Hubble Therapeutics key facts
- Developer of a gene therapy platform designed for a rare genetic eye disorder that typically presents with severe progressive visual impairment.
- It has raised $20.3M across 1 recorded rounds; the latest was Early Stage VC ($9.8M) in Oct 2024.
- Notable investors include WARF Ventures, Wisconsin Alumni Research Foundation, Bluestem Capital Company, Visionary Venture Fund.
- Hubble Therapeutics has filed 1 Form D with the SEC, most recently Oct 2024 ($9.8M sold to 17 investors).
- Status: Privately Held (backing).
Who backs Hubble Therapeutics
4- ·Watch Hubble Therapeutics: the Monday email on marks, rounds and moves
Hubble Therapeutics funding rounds
1 roundsHow much has Hubble Therapeutics raised?
Hubble Therapeutics has raised $20.3 million in total; 1 of its rounds is on record. The largest on record was a $9.8 million early-stage round in Oct 2024.
Hubble Therapeutics has filed 1 Form D with the SEC, most recently in Oct 2024 ($9.8 million sold to 17 investors).
Hubble Therapeutics investors
4 investors are on record for Hubble Therapeutics, including WARF Ventures, Wisconsin Alumni Research Foundation, Bluestem Capital Company and Visionary Venture Fund. The early-stage round in Oct 2024 drew 17 investors.
About Hubble Therapeutics
Developer of a gene therapy platform designed for a rare genetic eye disorder that typically presents with severe progressive visual impairment. The company's proprietary gene therapy treats leber congenital amaurosis, a rare genetic eye disorder, enabling patients to reverse that loss and restore sight with a single treatment.
- Sector
- Healthcare
- HQ
- Hanover, NH, United States
- Founded
- 2000
- Employees
- 2
- Website
- hubbletx.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.
Hubble Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.